TY  - CONF

T1  - Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.

JO  - CANCER RESEARCH

PY  - 2009/01/01

AU  - Malorni L

AU  - Hilsenbeck SG

AU  - Soliz RD

AU  - Ward RM

AU  - Ryan AJ

AU  - Osborne KC

AU  - Schiff R

ED  - 

VL  - 69

IS  - 24

SP  - 808S

EP  - 808S

Y2  - 2024/12/22

ER  -